Gene · 4921
Papers2,653
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 2,653
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Discovery of novel (E)-1-methyl-9-(3-methylbenzylidene)-6,7,8,9-tetrahydropyrazolo[3,4-d]pyrido[1,2-a]pyrimidin-4(1H)-one as DDR2 kinase inhibitor: Synthesis, molecular docking, and anticancer properties. | Bioorg Chem | 2023 | 37030105 | PubTator, text mining | PubMed |
| Effects of prenatal pesticide exposure on the fetal brain and placenta transcriptomes in a rodent model. | Toxicology | 2023 | 37019170 | PubTator, text mining | PubMed |
| Defining regorafenib as a senomorphic drug: therapeutic potential in the age-related lung disease emphysema. | Exp Mol Med | 2023 | 37009796 | PubTator, text mining | PubMed |
| Focusing on discoidin domain receptors in premalignant and malignant liver diseases. | Front Oncol | 2023 | 37007062 | PubTator, text mining | PubMed |
| Doxofylline ameliorates liver fibrosis by regulating the ferroptosis signaling pathway. | Front Pharmacol | 2023 | 37007035 | PubTator, text mining | PubMed |
| Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation. | Front Immunol | 2023 | 37006317 | PubTator, text mining | PubMed |
| Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers. | BMC Cancer | 2023 | 37004022 | PubTator, text mining | PubMed |
| Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. | Breast Cancer Res | 2023 | 36998014 | PubTator, text mining | PubMed |
| Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer. | PLoS Comput Biol | 2023 | 36996232 | PubTator, text mining | PubMed |
| Leveraging gene correlations in single cell transcriptomic data. | bioRxiv | 2023 | 36993765 | PubTator, text mining | PubMed |
| Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. | Vaccines (Basel) | 2023 | 36992198 | PubTator, text mining | PubMed |
| Dasatinib-Loaded Topical Nano-Emulgel for Rheumatoid Arthritis: Formulation Design and Optimization by QbD, In Vitro, Ex Vivo, and In Vivo Evaluation. | Pharmaceutics | 2023 | 36986597 | PubTator, text mining | PubMed |
| Screening of Differentially Expressed Genes Based on the ACRG Molecular Subtypes of Gastric Cancer and the Significance and Mechanism of AGTR1 Gene Expression. | J Pers Med | 2023 | 36983741 | PubTator, text mining | PubMed |
| From Minerals to Simplest Living Matter: Life Origination Hydrate Theory. | Acta Biotheor | 2023 | 36976380 | PubTator, text mining | PubMed |
| Biomimetic Remineralized Three-Dimensional Collagen Bone Matrices with an Enhanced Osteostimulating Effect. | Biomimetics (Basel) | 2023 | 36975321 | PubTator, text mining | PubMed |
| Biophysical cues of in vitro biomaterials-based artificial extracellular matrix guide cancer cell plasticity. | Mater Today Bio | 2023 | 36960095 | PubTator, text mining | PubMed |
| The Glioma-IRE project - Molecular profiling in patients with glioma: steps toward an individualized diagnostic and therapeutic approach. | J Transl Med | 2023 | 36959606 | PubTator, text mining | PubMed |
| Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden. | Front Oncol | 2023 | 36937383 | PubTator, text mining | PubMed |
| Patient-derived podocyte spheroids reveal new insights into the etiopathogenesis of Alport syndrome. | Front Cell Dev Biol | 2023 | 36936689 | PubTator, text mining | PubMed |
| Differential regulation of skeletal stem/progenitor cells in distinct skeletal compartments. | Front Physiol | 2023 | 36926193 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4921/papers?page=17